Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 1/20 | 0.49 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30688802 | 1.00 | NOTUM (0.57) | NOTUMCES2RXRARXRBRXRG | |
| SCHEMBL494019 | 0.93 | NOTUM (0.64) | NOTUMCES2RXRARXRBRXRG | |
| SCHEMBL28675044 | 0.87 | MRGPRX4 (0.44) | NOTUMCES2RXRARXRBRXRG | |
| SCHEMBL25677271 | 0.86 | NOTUM (0.57) | NOTUMCES2RXRARXRBRXRG | |
| SCHEMBL26334408 | 0.83 | NOTUM (0.46) | NOTUMRXRARXRBTAS2R14P2RY14 | |
| SCHEMBL503980 | 0.83 | CES2 (0.70) | CES2RXRARXRBRXRGP2RY14 | |
| SCHEMBL25186591 | 0.82 | PPARA (0.43) | NOTUMRXRARXRBRXRGTAS2R14 | |
| SCHEMBL30043720 | 0.82 | PPARA (0.43) | NOTUMRXRARXRBRXRGTAS2R14 | |
| Hydrochloric Acid SCHEMBL7485970 | 0.81 | CES2 (0.67) | CES2RXRARXRBRXRGP2RY14 | |
| SCHEMBL28119413 | 0.81 | CES2 (0.67) | CES2RXRARXRBRXRGP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2025-04-17 | — | — | US | disclosed |
| US-12227528-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2025-02-18 | — | — | US | disclosed |
| CN-117624207-A | Glucose-sensitive albumin binding derivatives | 诺和诺德股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-111315751-B | Glucose-sensitive albumin binding derivatives | 诺和诺德股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230331745-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2023-10-19 | — | — | US | disclosed |
| US-20230331745-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2023-10-19 | — | — | US | disclosed |
| US-11767332-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2023-09-26 | — | — | US | disclosed |
| US-11767332-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2023-09-26 | — | — | US | disclosed |
| EP-4227313-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | Novo Nordisk A/S (DK) | 2023-08-16 | — | — | EP | disclosed |
| EP-4227313-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | Novo Nordisk A/S (DK) | 2023-08-16 | — | — | EP | disclosed |
| EP-3707145-B1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2023-06-21 | — | — | EP | disclosed |
| EP-3707145-B1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-20220081451-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2022-03-17 | — | — | US | disclosed |
| US-11186595-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2021-11-30 | — | — | US | disclosed |
| US-20200325160-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK A/S (DK) | 2020-10-15 | — | — | US | disclosed |
| EP-3707145-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | Novo Nordisk A/S (DK) | 2020-09-16 | — | — | EP | disclosed |
| CN-111315751-A | Glucose-sensitive albumin binding derivatives | 诺沃挪第克公司 | 2020-06-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227528-B2 | Glucose-sensitive albumin-binding derivatives | ALB, DBI, FABP4 | NOTUM 2218/4885CES2 991/4885RXRA 3307/4885 |
| US-20230331745-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, DBI, FABP4 | NOTUM 2218/4885CES2 991/4885RXRA 3307/4885 |
| US-11767332-B2 | Glucose-sensitive albumin-binding derivatives | ALB, DBI, FABP4 | NOTUM 2218/4885CES2 991/4885RXRA 3307/4885 |
| US-20220081451-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, DBI, FABP4 | NOTUM 2218/4885CES2 991/4885RXRA 3307/4885 |
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, DBI, FABP4 | NOTUM 2218/4885CES2 991/4885RXRA 3307/4885 |
| US-11186595-B2 | Glucose-sensitive albumin-binding derivatives | ALB, GPR119, MLX | NOTUM 3555/4885CES2 816/4885RXRA 806/4885 |
| US-20200325160-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, GPR119, MLX | NOTUM 3555/4885CES2 816/4885RXRA 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.